Myelodysplastic Syndrome Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The myelodysplastic syndrome market size has grown rapidly in recent years. It will grow from $2.56 billion in 2024 to $2.85 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to increasing prevalence of myelodysplastic syndrome, growing awareness about myelodysplastic syndrome treatment, rising healthcare spending, government initiatives.

The myelodysplastic syndrome market size is expected to see strong growth in the next few years. It will grow to $4.17 billion in 2029 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to aging population, adoption of combination therapies, investment in hematologic research, personalized medicine. Major trends in the forecast period include innovative treatments for myelodysplastic syndrome, advancements in diagnostic tools and techniques, clinical trials, collaborative research.

The rising incidence of rare blood cancers is anticipated to drive the growth of the myelodysplastic syndrome (MDS) market in the coming years. Blood cancers, which are hematologic malignancies, have a low occurrence rate in the population and originate from the cells of the bone marrow, lymph nodes, and other blood and immune system components. MDS treatment focuses on managing the condition by enhancing blood cell production and addressing symptoms to prevent the progression of blood cancer in the bone marrow. For example, in September 2024, the Leukemia and Lymphoma Society, a U.S.-based professional organization, reported that every 3 minutes, one person in the U.S. is diagnosed with leukemia, lymphoma, or myeloma. In 2024, it is estimated that 187,740 individuals will be diagnosed with these cancers, making up 9.4% of the 2,001,140 new cancer cases expected in the U.S. Consequently, the growing incidence of blood cancers is driving the expansion of the myelodysplastic syndrome (MDS) market.

The expected rise in the number of bone marrow transplants is predicted to drive the growth of the myelodysplastic syndrome (MDS) market in the future. A bone marrow transplant is a medical procedure in which damaged or diseased bone marrow is replaced with healthy stem cells to treat various conditions. MDS is characterized by bone marrow failure, which results from the selective development of somatically altered clonal hematopoietic stem cells. Bone marrow transplantation can offer a potential cure for MDS by replacing abnormal stem cells with healthy ones. For example, in June 2024, the National Transplant Organization (ONT), a Spain-based independent coordinating agency, reported that in 2023, Spain added 23,686 new donors to the Spanish Bone Marrow Donor Registry, an 8% increase compared to 2022, and achieved a record 3,717 hematopoietic stem cell transplants, translating to 77.4 transplants per million population. Therefore, the increasing number of bone marrow transplants is driving the growth of the myelodysplastic syndrome market.

Key companies in the myelodysplastic syndrome (MDS) market are developing innovative therapies to enhance their market position. For example, in August 2023, Bristol Myers Squibb, a US-based pharmaceutical company, received FDA approval for Reblozyl (luspatercept-aamt) as a first-line treatment for anemia in ESA-naïve adults with low- to intermediate-risk MDS who may require regular RBC transfusions. In the Phase 3 COMMANDS trial, Reblozyl demonstrated superior efficacy in achieving RBC transfusion independence and increasing hemoglobin levels compared to epoetin alfa, providing earlier anemia management for a broader patient population.

In July 2022, GSK plc, a UK-based multinational pharmaceutical and biotechnology company specializing in vaccines and specialty medicines, acquired Sierra Oncology, Inc. for an undisclosed sum. This acquisition strengthens GSK's ability to develop innovative cancer therapies, enabling the company to better address unmet medical needs and enhance its position in the competitive pharmaceutical market, while furthering its commitment to improving patient outcomes in oncology. Sierra Oncology, Inc. is a US-based biopharmaceutical company focused on developing treatments for rare cancers, including myelodysplastic syndromes and primary myelofibrosis.

Major companies operating in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Medtronic PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.

North America was the largest region in the myelodysplastic syndrome market in 2024. The regions covered in myelodysplastic syndrome (MDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the myelodysplastic syndrome (MDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myelodysplastic syndrome (MDS) market consists of revenues earned by entities by providing experimental therapies, targeted therapies and blood transfusion. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelodysplastic syndrome (MDS) market also consists of sales of erythropoiesis-stimulating agents (ESAs) and immunomodulatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Myelodysplastic syndrome (MDS) encompasses a group of conditions characterized by the aberrant development and functioning of bone marrow cells, leading to inefficient production of blood cells. Treatment for myelodysplastic syndrome is aimed at enhancing blood cell counts, alleviating associated symptoms, and retarding the progression of the disease. It's noteworthy that myelodysplastic syndrome (MDS) can evolve into acute myeloid leukemia (AML), a more aggressive form of blood cancer.

Within the spectrum of myelodysplastic syndrome, various subtypes exist, including myelodysplastic syndrome with unilineage dysplasia, myelodysplastic syndrome with multilineage dysplasia, and myelodysplastic syndrome with ring sideroblasts. Myelodysplastic syndrome (MDS) with unilineage dysplasia is a specific classification within the range of MDS conditions. Treatment options for myelodysplastic syndrome encompass a range of drugs such as azacitidine, lenalidomide, decitabine, and deferasirox. Various treatment modalities are employed, including supportive therapy, growth factors, chemotherapy, and stem cell transplantation. These treatments can be administered through multiple routes, including oral, injectable, and others, and are delivered in diverse healthcare settings, such as hospitals, homecare, specialty centers, and more.

The myelodysplastic syndrome market research report is one of a series of new reports that provides myelodysplastic syndrome market statistics, including myelodysplastic syndrome industry global market size, regional shares, competitors with a myelodysplastic syndrome market share, detailed myelodysplastic syndrome market segments, market trends and opportunities and any further data you may need to thrive in the myelodysplastic syndrome industry. This myelodysplastic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.